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Ageing and amyloidosis underlie 
the molecular and pathological 
alterations of tau in a mouse model 
of familial Alzheimer’s disease
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Despite compelling evidence that the accumulation of amyloid-beta (Aβ) promotes neocortical MApt 
(tau) aggregation in familial and idiopathic Alzheimer’s disease (AD), murine models of cerebral 
amyloidosis are not considered to develop tau-associated pathology. In the present study, we show that 
tau can accumulate spontaneously in aged transgenic APPswe/PS1ΔE9 mice. Tau pathology is abundant 
around Aβ deposits, and further characterized by accumulation of Gallyas and thioflavin-S-positive 
inclusions, which were detected in the APPswe/PS1ΔE9 brain at 18 months of age. Age-dependent 
increases in argyrophilia correlated positively with binding levels of the paired helical filament (PHF) 
tracer [18F]Flortaucipir, in all brain areas examined. Sarkosyl-insoluble PHFs were visualized by electron 
microscopy. Quantitative proteomics identified sequences of hyperphosphorylated and three-repeat 
tau in transgenic mice, along with signs of RNA missplicing, ribosomal dysregulation and disturbed 
energy metabolism. Tissue from the frontal gyrus of human subjects was used to validate these 
findings, revealing primarily quantitative differences between the tau pathology observed in AD 
patient vs. transgenic mouse tissue. As physiological levels of endogenous, ‘wild-type’ tau aggregate 
secondarily to Aβ in APPswe/PS1ΔE9 mice, this study suggests that amyloidosis is both necessary and 
sufficient to drive tauopathy in experimental models of familial AD.
Genetically-inherited and sporadic forms of Alzheimer’s disease (AD) are characterized by a common set of 
hallmark brain lesions, which include the aggregation of amyloid-β (Aβ) peptide into fibrillar plaques, neuroin-
flammation, aggregation of hyperphosphorylated MAPT (tau) protein into neurofibrillary tangles (NFTs), and 
neurodegeneration. Transgenic mouse models that reproduce the amyloid aggregation and glial activation due to 
Aβ overexpression have been generated based on mutations in the amyloid precursor protein (APP) and prese-
nilin 1 (PSEN1) and 2 (PSEN2) genes, which are known to cause familial AD1. Despite playing important roles 
in evaluating APP processing, Aβ toxicity and amyloid-targeting therapeutic strategies, transgenic mice are not 
being regarded as models that can replicate the full spectrum of AD histopathology2. In particular, while the 
overexpression of mutant APP and APP/PSEN1 yields amyloidosis3, neuroinflammation4 and degeneration of 
monoaminergic5 and cholinergic6 neurons, it is generally not considered sufficient to cause aggregation of endog-
enous murine tau into neurofibrillary structures7.
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To address the role of tau hyperphosphorylation and NFT formation in AD pathogenesis, human MAPT 
(TAU) has been introduced into the mouse genome, either mutated or non-mutated, on a tau-knockout back-
ground8,9. TAU expressing mice demonstrate progressive neurofibrillary pathology, albeit in the absence of 
cerebral amyloidosis which is required for a neuropathological diagnosis of AD. Moreover, mutations in TAU 
have been linked to non-AD tauopathies, most commonly frontotemporal lobar degeneration [FTLD10], a con-
dition with neuropathological hallmarks distinct from AD. Thus, murine models of amyloidosis and combined 
amyloidosis-tauopathy models have been widely criticized for their translational relevance to human AD. It has 
been argued that virtually all existing murine models would be considered as ‘not’ AD11 according to the ABC 
scoring system of neuropathology12. The inability of amyloidosis mice to develop neurofibrillary tau lesions is 
thought to contribute to the poor translation of preclinical research into clinical benefits13, and has raised concern 
about the amyloidocentric model of AD pathogenesis14.
Several factors have been proposed to account for the lack of tau-associated pathology in amyloidosis models. 
It has been suggested that the development of tauopathy in AD requires an imbalance in the expression of tau 
protein isoforms containing three (3R) and four (4R) microtubule-binding repeat domains15,16. By predominantly 
expressing 4R tau in the brain17, adult mice might be less susceptible to tau accumulation than species express-
ing both 3R and 4R isoforms, such as humans18 and rats19. However, murine20, rat21 and human22 tau have been 
shown to readily fibrillize in vitro upon treatment with polyanionic factors, indicating that tau’s propensity for 
aggregation is neither isoform, nor species-dependent. In addition, hallmark post-translational modifications 
(PTMs) that are associated with the accumulation of fibrillar tau in AD, such as phosphorylation23, have been 
detected in the brain of transgenic mice24, including APPswe/PS1ΔE9 mice (Supplementary Table S1). A third rea-
son that is often cited for the absence of tau pathology in amyloidosis models is that the murine lifespan may be 
too short for the complete sequence of neurofibrillary pathology to unfold in transgenic mice25. Although age 
scaling studies suggest otherwise26, the ageing factor has been neglected in the design of preclinical studies.
The present study was based on evidence that murine tau aggregates into paired helical filaments (PHFs) in 
vitro, becoming hyperphosphorylated during the course of amyloidosis in the transgenic mouse brain. We rea-
soned that murine models of familial AD may spontaneously develop neurofibrillary pathology, provided they 
are sufficiently aged. Using techniques that are complimentary in their ability to detect fibrillar tau, we report 
that cortical tau-associated pathology develops secondarily to amyloidosis in APPswe/PS1ΔE9 mice. The observed 
pathology is characterised by aggregation of hyperphosphorylated tau and participation of both 3R and 4R iso-
forms. These results show that it is possible to model the relationship between aberrant APP processing and tau 
pathology in a translationally-relevant manner.
Results
neurofibrillary pathology in aged Appswe/PS1ΔE9 mice. Fresh-frozen brain sections from 
APPswe/PS1ΔE9 transgenic (TG) mice and their wild-type (WT) counterparts were processed along with human 
brain sections for the detection of neurofibrillary alterations with the Gallyas silver stain. Co-staining for amyloid 
and Gallyas was used to probe the relationship between amyloidosis and tau-associated pathology.
Aβ deposition was the predominant lesion in the 6-month-old APPswe/PS1ΔE9 brain (Fig. 1a,b), with 
age-dependent increases in argyrophilic density observed exclusively in TG mice (Fig. 1c-f). Only mild and 
diffuse silver staining was observed in the neocortex of 6-month-old animals (Fig. 1g). Densely-labelled, 
plaque-like structures, surrounded by a halo of argyrophilic staining, constituted the majority of Gallyas-positive 
signal in the neuropil of the neocortex and hippocampus at 12–24 months of age (Fig. 1h,i). In addition, dif-
fuse and compact argyrophilic staining was observed surrounding red-stained nuclei in the neocortex of 18 and 
24-month-old APPswe/PS1ΔE9 mice (Fig. 1j,k). The perinuclear structures were positive for thioflavin-S (Fig. 1l–n). 
Thioflavin-S colocalized with nuclear DAPI (Fig. 1o) and was further detected in cell-sized structures lacking a 
stainable nucleus (Fig. 1p). There were no apparent differences in morphology between the argyrophilic struc-
tures in brain tissue from 24-month-old TG mice (Fig. 1q–u) and AD-confirmed patient material (Fig. 1v–z), 
although silver-stained neuropil threads were detected exclusively in AD tissue (Fig. 1q–z). Coronal brain sec-
tions of 20-month-old Tg2576 mice, harbouring the Swedish double mutations, were used to examine 6E10- and 
Gallyas-positive pathology in a second mouse model of amyloidosis (Fig. 1aa–ad). Amorphous argyrophilic sig-
nal (ac) and perinuclear lesions (ad) were detected in the Tg2576 mouse brain, albeit at lower levels compared to 
18-month-old APPswe/PS1ΔE9 mice.
The fraction of brain tissue occupied by Gallyas-positive staining in APPswe/PS1ΔE9 mice is shown in Fig. 2. 
Approximately 4-fold higher levels of argyrophilic staining were measured in the positive control AD section 
(3.9%) compared to the 24-month-old APPswe/PS1ΔE9 neocortex (0.96%). Vascular and meningeal lesions were 
present in 18 and 24-month-old animals (Supplementary Fig. S1).
Age-dependent increase in [18f]flortaucipir binding levels in APPswe/PS1ΔE9 mice. The PHF 
ligand [18F]Flortaucipir ([18F]AV-1451, [18F]T807) was used to quantify tau pathology in APPswe/PS1ΔE9 TG 
mice by autoradiography (Table 1). Increased binding was observed in the neocortex, hippocampus, amygdala 
and the cerebellum of 12-month-old APPswe/PS1ΔE9 mice, compared to age-matched WT animals, and vs. 3 and 
6-month-old TG mice (P < 0.001 for all regions; Bonferroni post-hoc tests). [18F]Flortaucipir binding was fur-
ther elevated in the visual (P < 0.001), somatosensory (P < 0.001), motor cortex (P < 0.001), and the amygdala 
(P < 0.05) of 18 vs. 12-month-old APPswe/PS1ΔE9 TG mice. Increased binding over age-matched control mice was 
first observed in the thalamus of TG animals at 18 months of age (P < 0.001). In 24-month-old APPswe/PS1ΔE9 
mice, [18F]Flortaucipir signal had increased in all brain regions examined compared to age-matched controls. 
Three-way ANOVA confirmed genotype- [F(1,476) = 2603.1, P < 0.001], age- [F(4,476) = 457.3, P < 0.001] and brain 
region-specific increases in the binding levels of [18F]Flortaucipir [F(9,476) = 42.9, P < 0.001], as well as signif-
icant age × genotype × region interaction effects [F(36,476) = 5.5, P < 0.001]. Representative autoradiograms of 
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Figure 1. Neurofibrillary alterations in amyloidosis mice. a&b Sagittal brain sections of 6-month-old 
APPswe/PS1ΔE9 mice, processed for 6E10 immunohistochemistry (a) and the Gallyas silver stain (b). Silver-
labelled sections were counterstained with nuclear fast red. β-amyloidosis dominates over argyrophilic 
pathology in the neocortex of 6-month-old APPswe/PS1ΔE9 mice. (c–f) Progressive increase in Gallyas-positive 
signal in 12 (c), 18 (d), and 24-month-old transgenic (TG) mice (e). Wild-type animals showed no silver 
deposition up to 24 months of age (f). (g–p) All photomicrographs are from the neocortex of APPswe/PS1ΔE9 
mice. Argyrophilic signal was scarce in 6-month-old TG animals (g). Gallyas-positive structures in 18 (h) and 
24-month-old animals (i), likely of neuritic nature. Gallyas silver (j,k) and thioflavin-S stainings (l–p), showing 
perinuclear and intranuclear signal in 18- and 24-month-old TG mice. The insert in j shows compact Gallyas 
staining in the absence of nuclear fast red. Note potential fragmented nuclei in (m) and (n), intranuclear signal 
in (o), and absence of DAPI signal in (p). (q–z) Gallyas/6E10 double-labelled sections from a 24-month-old 
TG mouse (q–u) and an AD patient (v-z), showing dense-core plaques (q,v), teardrop-shaped structures (r,w, 
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[18F]Flortaucipir binding sites are shown in Fig. 3(A–C). Binding was abolished in the presence of 50 µM unla-
belled Flortaucipir (Fig. 3B), but was not blocked by 1 µM of the beta sheeted amyloid-marker Pittsburgh com-
pound B (PIB; Fig. 3C). [18F]Flortaucipir binding levels in 3 consecutive sections of the AD-confirmed neocortex 
were 4-fold higher compared to the neocortex of 24-month-old APPswe/PS1ΔE9 mice (191.3 ± 7.1 kBq/mL vs. 
53.6 ± 6.1 kBq/mL).
Within each brain area analysed, there was a positive correlation between the age-dependent increase in the 
binding levels of [18F]Flortaucipir and the progressive increases in the density of Gallyas-positive lesions (Pearson 
r for all brain regions: 0.92, P < 0.001; Table 1).
Unaltered Mapt expression in ageing Appswe/PS1ΔE9 mice. Relative expression of total Mapt mRNA 
was determined by RT-qPCR (Supplementary Fig. S2). There were no age [F(4,50) = 0.29, P > 0.05], genotype 
[F(1,50) = 0.93, P > 0.05], or age × genotype interaction effects on the expression levels of Mapt [F(4,50) = 1.21, 
P > 0.05].
Isolation and transmission electron microscopy (TEM) of sarkosyl-insoluble tau. The gen-
eral methods of Sahara et al.27 and Greenberg and Davies28 were evaluated for the extraction of PHFs from the 
24-month-old TG brain (Supplementary Fig. S3). Although longer filaments were isolated by the procedure of 
Sahara et al., the Greenberg and Davies method was chosen for the isolation of sarkosyl-insoluble tau from 3 and 
24-month-old mice, based on immunoblotting experiments, solubility considerations, and to allow for compari-
sons with literature data29. Soluble and insoluble tau levels were measured in mouse brain homogenates by using 
the mouse Total Tau Meso Scale kit (Meso Scale Diagnostics LLC). TEM was used to visualize filaments in the 
sarkosyl-insoluble extracts from the mouse and AD patient brains by negative staining.
Tau protein levels increased with age in the pellet obtained by centrifuging WT and APPswe/PS1ΔE9 homogen-
ates at 27,000 × g [Fig. 4A; age effect: F(1,18) = 50.0, P < 0.001; genotype effect: F(1,18) = 2.4, P > 0.05]. Levels of tau 
in the supernatant fraction were not different between 3 and 24-month old, WT and APPswe/PS1ΔE9 TG mice [age: 
F(1,16) = 0.6, P > 0.05; genotype: F(1,16) = 0.0, P > 0.05]. Treatment of the supernatant with 1% sarkosyl for 2 h at 
37 °C increased the concentration of tau in the detergent-soluble fraction by > 3-fold. Sarkosyl-soluble tau levels 
were lower in the 24 vs. 3-month-old mouse brain [F(1,16) = 12.5, P < 0.01], irrespective of genotype [F(1,16) = 0.5, 
P > 0.05]. Sarkosyl-insoluble tau was not detected in 3-month-old animals, and its levels were not different 
between 24-month-old APPswe/PS1ΔE9 and WT mice [t(8) = 0.7, P > 0.05; independent two-tailed Student’s t-test].
Negative stains of sarkosyl-insoluble lysates from 24-month-old mice and AD patient brain are shown in 
Fig. 4B. No filaments were observed in 24-month-old WT mice (a). Fibrils of mean length 104.9 ± 8.3 nm and 
width 10.1 ± 0.5 nm were isolated from aged TG mice (b). Wider fibrils (~20 nm), with or without a pronounced 
twist, were readily detected in both TG (c) and AD patient material (g). Longer filaments (271.7 ± 11.3 nm), 
with axial periodicities of 78.7 ± 9.8 nm, constituted ~8% and ~34% of the fibril population analysed in the 
APPswe/PS1ΔE9 (d) and AD brains (h), respectively. Clusters of long filaments, which were denser in AD patient 
material, were present in the insoluble preparation from APPswe/PS1ΔE9 mice (d & h, inserts). There were no 
between-species differences in the dimensions of the isolated filaments [short filaments, length: t(82) = 0.1, 
P > 0.05, width: t(82) = 1.2, P > 0.05; long filaments, length: t(16) = 0.3, P > 0.05, width: t(16) = 0.8, P > 0.05; inde-
pendent two-tailed t-tests]. In addition to straight and helical filaments, thin/bent fibrils (e & i) and rod-shaped 
particles (f & j) were observed in both 24-month-old TG mice (e & f) and AD brains (i & j). Rod-shaped, granular 
particles were observed in two of three independent experiments using lysates from aged WT mice.
Proteomics of sarkosyl-insoluble tau. The sarkosyl-insoluble fractions extracted from 3 and 
24-month-old mouse brain, AD and non-AD material, were digested with trypsin & Lys-C. The pep-
tides were labelled with Tandem Mass Tags (TMT), pooled 1:1, fractionated, and analysed by nanoLiquid 
Chromatography-Electrospray Ionization Mass Spectrometry (LC-ESI MS/MS). A list of tau-associated pro-
teins quantified in the sarkosyl-insoluble proteome is shown in Table 2. Lists of all identified proteins and 
between-group abundance ratios are provided as a Supplementary Dataset.
There were 583 proteins identified in the sarkosyl-insoluble mouse proteome, of which 456 were also present 
in the human samples. Isoforms of tau with three (3R) and four (4R) microtubule-binding repeats were extracted 
from both human and the murine brain. In mice, all tau isoforms collapsed under the term microtubule asso-
ciated protein (MAP; UniProt accession number: B1AQW2). Mouse MAP was regulated by age, rather than 
genotype. The protein was enriched 2.1-fold in 24 vs. 3-month-old TG mice, and 1.8-fold in 24 vs. 3-month-old 
WT mice. Individual isoforms of tau were differentially regulated between APPswe/PS1ΔE9 and WT mice. Tau 
isoform-B (UniProt accession number: P10637-3), containing the motif 205KVQIVYKPVDLSKV218, is a 3R iso-
form with an extended C-terminal domain, which was increased 3.2-fold in 24-month-old TG vs. WT mice, and 
4.5-fold in 24 vs. 3-month-old TG animals. Human MAP (UniProt accession number: A0A0G2JMX7), contain-
ing tau isoforms P10637-2, -4, -6 & -8, was 37-fold enriched in the sarkosyl-insoluble fraction of AD compared 
to non-AD brain.
Although levels of unmodified tau were not different between age-matched WT and TG mice, the mouse 
MAP sequence 174KVAVVRTPPKSPSASKS190, phosphorylated at Threonine (T) 180 and Serine (S) 188, 
arrows), tuft-shaped filaments (s,x, arrows), and globose structures in close proximity (t,y) and over 200 µm 
afar from Aβ deposits (u,z). (aa–ad) 6E10/Gallyas- (aa) and Gallyas-labelled (ab-ad) sections of 20-month-old 
Tg2576 mice. Scale bar is 2 mm for a&b, 1 mm for c-f, 10 µm for g-i, 5 µm for j-p, 10 µm for q & v, 20 µm for r-u 
& w-z, 200 µm for aa&ab, 20 µm for ac, and 5 µm for ad.
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was more than 20-fold enriched in 24-month-old APPswe/PS1ΔE9 mice compared to age-matched WT and 
3-month-old TG mice. The hyperphosphorylated sequence was not regulated in 24 vs. 3-month-old WT ani-
mals. An orthologous sequence of the human MAP was phosphorylated at Threonine (T) 566 and Serine (S) 
573 (560KVAVVRTPPKSPSSAKS576). The reported phosphorylation sites correspond to amino acids (aa) T231 
Figure 2. Quantification of Gallyas-positive signal in APPswe/PS1ΔE9 mice. Regions of interest were manually 
drawn by reference to the mouse brain atlas of Paxinos and Franklin76. Gallyas-positive particles were measured 
with the particle analysis plugin in ImageJ, after thresholding ROIs on a black and white image display mode, 
by using default software settings. Data are presented as the mean area fraction occupied by Gallyas-positive 
particles ± standard error of the mean (SEM), in brain regions of 5–6 animals/group. Asterisks denote increased 
argyrophilia compared to 3-month-old APPswe/PS1ΔE9 mice (*P < 0.05, **P < 0.01, ***P < 0.001, Bonferroni 
post-hoc tests). When all brain regions were analysed together, increased silver deposition was detected in 12 
vs. 3 and 6-month-old APPswe/PS1ΔE9 mice (P < 0.001), with additional accumulation occurring in 18- vs. 
12- (P < 0.001), and 24- vs. 18-month-old TG animals (P < 0.05, Bonferroni post hoc tests). Two-way ANOVA 
confirmed significant main effects of age [F(4,245) = 169.9, P < 0.001] and brain region [F(9,245) = 11.4, P < 0.001], 
as well as significant age × region interaction effects on the fraction of brain tissue bearing Gallyas-positive 
signal [F(36,245) = 3.2, P < 0.001].
Brain region 3 months 6 months 12 months 18 months 24 months
Correlation with 
Gallyas-positive 
fraction
Cortical WT APP/PS1 WT APP/PS1 WT APP/PS1 WT APP/PS1 WT APP/PS1
Pearson r 
(Significance)
Frontal 2.2 ± 0.7 3.6 ± 1.3 2.3 ± 0.9 10.0 ± 1.6 4.0 ± 1.0 46.7 ± 2.7*** 4.7 ± 1.1 53.2 ± 3.0 4.2 ± 1.0 55.2 ± 5.7 0.74 (P < 0.001)
Motor 2.5 ± 0.5 2.8 ± 0.8 2.5 ± 0.7 7.3 ± 1.3 3.2 ± 0.7 31.0 ± 1.3*** 3.2 ± 0.8 45.1 ± 2.0 4.3 ± 1.1 55.7 ± 2.9 0.90 (P < 0.001)
Somatosensory 5.2 ± 1.3 5.0 ± 2.0 4.0 ± 0.9 11.6 ± 1.9 6.7 ± 4.5 34.9 ± 2.6*** 6.5 ± 1.8 50.3 ± 1.5 5.8 ± 1.6 57.8 ± 2.7 0.93 (P < 0.001)
Visual 6.8 ± 2.4 4.7 ± 1.4 2.4 ± 1.1 11.8 ± 2.5 8.2 ± 1.8 35.5 ± 3.2*** 6.3 ± 1.9 52.9 ± 2.8 5.0 ± 1.3 56.4 ± 2.9 0.92 (P < 0.001)
Entorhinal 3.2 ± 1.0 2.9 ± 1.0 3.3 ± 0.8 8.8 ± 1.1 6.7 ± 1.5 29.8 ± 1.9*** 4.1 ± 2.6 40.6 ± 3.8 6.3 ± 1.7 42.8 ± 4.0 0.84 (P < 0.001)
Subcortical
Hippocampus 3.1 ± 1.3 2.8 ± 0.8 3.0 ± 0.7 7.5 ± 1.3 4.3 ± 1.3 31.3 ± 2.4*** 4.3 ± 1.2 40.9 ± 2.5 5.6 ± 1.5 49.1 ± 3.1 0.86 (P < 0.001)
Striatum 2.6 ± 1.4 3.1 ± 1.0 3.1 ± 0.7 4.8 ± 0.9 4.4 ± 1.1 10.9 ± 2.4 5.1 ± 1.5 17.2 ± 1.2 5.4 ± 1.5 19.7 ± 2.8** 0.64 (P < 0.001)
Amygdala 1.8 ± 1.5 2.9 ± 0.9 3.1 ± 0.7 7.4 ± 1.0 4.2 ± 1.1 27.8 ± 2.9*** 5.2 ± 1.5 40.0 ± 2.5 5.2 ± 1.1 47.7 ± 4.8 0.79 (P < 0.001)
Thalamus 2.6 ± 0.6 2.2 ± 0.6 3.3 ± 1.0 3.5 ± 0.5 3.6 ± 0.9 11.2 ± 3.2 3.9 ± 1.3 17.5 ± 2.0*** 4.1 ± 1.0 27.2 ± 4.5 0.87 (P < 0.001)
Cerebellum 4.2 ± 0.8 3.1 ± 1.1 4.1 ± 1.2 10.3 ± 1.1 3.3 ± 1.0 23.0 ± 3.1*** 4.5 ± 1.5 31.2 ± 3.6 5.8 ± 1.6 32.4 ± 3.7 0.83 (P < 0.001)
Mean binding levels 
(all brain regions) 3.4 ± 1.1 3.3 ± 1.1 3.1 ± 0.9 8.3 ± 1.3 4.9 ± 1.5 28.2 ± 2.6 4.8 ± 1.5 38.9 ± 2.5 5.2 ± 1.3 44.4 ± 3.7 0.92 (P < 0.001)
Table 1. Autoradiography of [18F]Flortaucipir binding sites in APPswe/PS1ΔE9 mice. Fresh-frozen brain sections 
from APPswe/PS1ΔE9 and age-matched wild-type (WT) animals were incubated with 38.4 ± 9.6 MBq [18F]
Flortaucipir for a period of 60 min (specific activity: 145 ± 68 GBq/µmol). Autoradiography data are presented 
as the mean specific binding of [18F]Flortaucipir (kBq/mL) ± standard error of the mean in brain regions of 5–6 
animals/group. By 24 months of age, [18F]Flortaucipir binding in APPswe/PS1ΔE9 mice had increased across all 
brain areas examined compared to age-matched WT animals. The age-dependent increase in [18F]Flortaucipir 
binding levels was positively correlated with the progressive increase in Gallyas-positive argyrophilic signal, in 
all TG brain areas examined. **P < 0.01, ***P < 0.001 vs. age-matched littermate control mice, Bonferroni post-
hoc tests. Symbols of significant differences between groups of 24 & 18 vs. 3, 6 and 12-month-old-mice were 
omitted from the table for clarity of presentation.
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and S238 of the human tau isoform with 441 aa. Indications of additional phosphorylation sites were obtained 
by searching modified peptides against tau isoform- and species-specific databases. Phosphorylated S396, S400 
and S404 on the conserved sequence 396SPVVSGDTSPR406 of the human 441 aa isoform were identified in the 
sarkosyl-insoluble mouse proteome, and were > 2.0-fold enriched in 24-month-old TG vs. WT mice. In addition 
to phosphorylation, murine MAP was deamidated at Asparagine (N) 44, a site on the N-terminal domain of tau 
that is not conserved in humans (34AEEAGIGDTPNQEDQAAGHVTQAR57). Human MAP was deamidated at 
position N484, corresponding to N167 of the 441 aa tau isoform (473GAAPPGQKGQANATRIPAK491).
The database for annotation, visualization and integrated discovery (DAVID, v6.8) was used for gene ontol-
ogy (GO) enrichment analysis of the sarkosyl-insoluble proteome30,31. RNA splicing, mRNA processing and 
translation were among the 10 most enriched biological processes associated with protein upregulation in 
24-month-old APPswe/PS1ΔE9 vs. WT mice and AD vs. non-AD subjects. Ribonucleoprotein complexes, ribo-
somes, and exosomes were among the 10 most enriched cellular components in the insoluble extracts from the 
mouse and human brain (Fig. 5A). The top 10 molecular functions of the enriched proteins were associated 
with poly(A) RNA binding, as well as binding of molecules contributing to the structural integrity of ribosomes 
and the cytoskeleton (Fig. 5B). Pathway-based enrichment analysis of upregulated proteins in 24-month-old 
APPswe/PS1ΔE9 vs. WT mice involved GO terms such as Alzheimer’s and Huntington’s disease, long-term depres-
sion, cholinergic, serotonergic and glutamatergic synapse (Fig. 5C). Glycolysis/gluconeogenesis and the Krebs 
cycle were among the top 10 pathways for downregulated proteins (Fig. 5D).
Validation of pS404, pT231 and 3R tau. Phosphorylation at the S404 residue of sarkosyl-insoluble tau 
was confirmed in 24-month-old APPswe/PS1ΔE9 mice by immunoblotting (Fig. 6A). New samples were gener-
ated to compare the levels of soluble and insoluble, pT231 and 3R tau in TG vs. WT mice. Levels of soluble 
pT231 increased with age in the neocortex [F(1,20) = 8.4, P < 0.01], irrespective of genotype [F(1,20) = 0.0, P > 0.05; 
Fig. 6B]. The effect was small, and individual Bonferroni comparisons showed no differences in pT231 tau con-
centration between 3 and 24-month-old mice (P > 0.05). Sarkosyl-insoluble pT231 tau was observed exclusively 
in 24-month-old TG animals (Fig. 6B). Immunohistochemistry of pT231 tau in free-floating sections from 3- and 
18-month-old WT and TG mice is shown in Fig. 6C. Stronger immunoreactivity was observed in the cell soma 
of 18 vs. 3-month-old animals. Additionally, pT231 immunoreactive puncta were observed within plaque-like 
structures, exclusively in the neocortex of aged TG mice. For 3R tau (Fig. 6D), low levels of soluble protein were 
Figure 3. Representative autoradiograms of [18F]Flortaucipir binding sites. (A) Sagittal brain sections of 
transgenic (top panel) and wild-type mice (WT, lower panel), taken at the level of the entorhinal cortex 
[lateral 2.88 ± 0.12 mm of the Paxinos and Franklin mouse atlas76]. Images were analysed on a black & white 
display mode, and presented as a pseudocolor interpretation of black & white pixel intensity, calibrated in 
kBq/mL of [18F]Flortaucipir solution. Age-dependent increases in binding levels were observed exclusively 
in APPswe/PS1ΔE9 mice. (B) [18F]Flortaucipir binding in sections from the middle frontal gyrus of an AD-
confirmed patient, 18-month-old APPswe/PS1ΔE9 mice and 20-month-old Tg2576 animals, showing the 
magnitude of tau pathology in patient vs. transgenic mouse tissue. Non-specific binding (NSB) was assessed 
in the presence of 50 µM ‘cold’ flortaucipir. (C) Binding was not blocked by co-incubating sections with [18F]
Flortaucipir and 1 µM of the amyloid-targeting agent Pittsburgh Compound B (PIB).
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identified in the neocortex of both TG and WT mice by ELISA. There was no genotype effect on the concen-
tration of soluble 3R tau [F(1,20) = 0.9, P > 0.05]. Ageing increased 3R tau levels in the neocortex [F(1,20) = 6.8, 
P < 0.05], but the effect was small, and Bonferroni post-hoc tests showed no differences in 3R tau concentration 
between 24 and 3-month-old animals (P > 0.05). In the sarkosyl-insoluble fraction, 3R tau was only observed in 
24-month-old TG mice. RT-qPCR data of Mapt isoform-B mRNA and immunoblotting of PBS-soluble 3R tau are 
shown in Supplementary Fig. S4.
Figure 4. Isolation and electron microscopy of sarkosyl-insoluble tau. (A) Levels of soluble and insoluble tau 
were determined with the mouse Total Tau Meso Scale kit. Tau levels increased with age in the pellet obtained 
by centrifuging brain homogenates at 27,000 × g. The resulting supernatant was treated with 1% sarkosyl and 
centrifuged at 200,000 × g. The solubility of tau in sarkosyl decreased with age, irrespective of genotype. (B) 
Overview of negatively-stained material in sarkosyl-insoluble lysates from (a) aged wild-type (WT) and (b) aged 
APPswe/PS1ΔE9 transgenic (TG) mice. Fibrils of ~20 nm in width, appearing as straight filaments (c) or as two 
intertwined fibrils (g), each with a diameter of ~10 nm. PHFs with axial periodicities of ~80 nm were present in 
APPswe/PS1ΔE9 mice (d; arrows), and more frequently observed in AD patient material (h; arrows). The inserts 
show ‘stacked’ PHFs, which were denser in the AD preparation. Structures identified in the detergent-insoluble 
fractions of the mouse and human brain included bent fibrils of ~7 nm in width (e,i), and rod-shaped particles 
(arrows e & f; insert a). Scale bars: 1 µm (a, b); 200 nm (c,d,g,h); 100 nm (e,f,i,j; insert a).
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Discussion
Tau protein hyperphosphorylation has been observed in various regions of the APPswe/PS1dE9 brain. The present 
study confirms and extends this literature, by showing that hyperphosphorylated tau converts into neurofibril-
lary structures in aged transgenic APPswe/PS1dE9 and Tg2576 mice. Neurofibrillary alterations in these mice were 
demonstrated by a set of tools that preferentially label insoluble tau in human AD, such as the Gallyas silver stain32 
and [18F]Flortaucipir33. Straight and helical filaments were visualised by TEM of sarkosyl-insoluble preparations 
from the 24-month-old APPswe/PS1ΔE9 brain. As murine tau possesses a remarkably high number of potential 
serine/threonine (76) and tyrosine (4) phosphorylation sites, an unbiased proteomics approach was used for the 
identification and quantification of hyperphosphorylated tau epitopes. Of the five residues identified, pT231 and 
pS404 have been associated with early and late stages of tau aggregation, respectively34,35. The pathology observed 
in the present study occurred at physiological levels of endogenous tau, as there was no difference in total tau 
mRNA and protein between APPswe/PS1ΔE9 and WT mice. These results indicate that, in addition to amyloidosis3, 
neuroinflammation4 and neurodegeneration5, APPswe/PS1ΔE9 mice exhibit face validity for the neurofibrillary 
lesions of AD.
Post-mortem36 and in vivo imaging data37 reveal that the development of cortical tau pathology in AD patients 
is associated with, and may depend on, pre-existing β-amyloid plaque pathology. Aβ deposition has also been 
UniProt
Protein (Sequence) Involvement
TG vs. 
WT
TG vs. 
WT TG WT
AD vs. non-ADAccession Number 3 M 24 M 24 vs. 3 M 24 vs. 3 M
B1AQW2
Microtubule-associated protein Tau 0.86 1.00 2.06 1.77 37.15
(KVAVVRTPPKSPSASKS) pT231 0.87 26.55 23.81 0.78 0.94
(KSPVVSGDTSPRH) pS396, pS400, pS404 1.46 2.02 1.00 0.67 1.16
P10637-3 Microtubule-associated protein tau Tau Isoform-B 0.61 3.21 4.52 0.86 Fetal form present
Multiple Small nuclear ribonucleoproteins (SnRPN) Core spliceosomal components Age- and genotype-specific regulation (Supplementary Dataset)
Multiple Heterogeneous nuclear ribonucleoproteins Exon 10 splicing regulation Multiple proteins regulated (Supplementary Dataset)
Q8BL97 Serine/arginine-rich splicing factor 7 Exon 10 exclusion 0.82 1.05 1.11 0.87 0.69
Q9Z0H4 CUGBP Elav-like family member 2 Exon 10 exclusion 0.40 1.85 1.94 0.42 1.49
P62996 Transformer-2 protein homolog beta Exon 10 inclusion 0.85 1.13 0.74 0.56 Not identified
Multiple Tubulin Tau binding partner Alpha & beta chains regulated (Supplementary Dataset)
P60710 Actin, cytoplasmic 1 Tau binding partner 0.80 0.53 1.43 2.16 0.71
P08551, P08553, P19246 Neurofilament Tau binding partner Light, medium & heavy polypeptides regulated (Supplementary Dataset)
Multiple Ribosomal proteins60 S, 40 S Tau binding partner
Age- and genotype-specific changes, particularly in the acidic proteins of 
the 60 S subunit (Supplementary Dataset)
O08788 Dynactin Tau binding partner 1.01 1.34 0.79 0.59 Not identified
P28738 Kinesin Tau binding partner 0.92 0.75 1.03 1.28 0.90
P11499, Q80Y52, Q3UAD6 Heat shock protein 90 Tau binding partner Isoforms alpha & beta identified (Supplementary Dataset)
P48722, P17156, Q3U2G2, 
Q8K0U4 Heat shock protein 70 Tau binding partner Members 2 & 4 common in mice & humans (Supplementary Dataset)
P0DP26 Calmodulin-1 Tau binding partner 1.68 0.31 0.68 3.63 0.93
Q3UY00 S100β Tau binding partner 0.99 0.52 1.27 2.44 0.34
O55042 α-Synuclein Tau binding partner 0.81 0.70 1.29 1.49 0.79
A8IP69, P68510, F6VW30, 
Q9CQV8, P63101 14-3-3 proteins Tau binding partner Isoform-specific changes (Supplementary Dataset)
Q3TXU4 Apopoliprotein E Tau binding partner/AD risk factor 0.65 3.58 7.51 1.37 Not identified
O08539 Bin 1 Tau binding partner/AD risk factor 2.11 0.44 0.71 3.41 1.44
Q549A5 Clusterin Tau interacting partner AD risk factor 1.17 1.82 1.87 1.20 Not identified
P11798, Q923T9, 
A0A0G2JGS4
Ca2+/calmodulin-dependent 
protein kinase II Tau kinase Multiple subunits identified (Supplementary Dataset)
P63318 Protein kinase C,gamma type Tau kinase 0.71 1.48 1.30 0.62 1.05
P31324 Cyclic-AMP dependent protein kinase II Tau kinase 0.57 0.91 1.61 1.01 0.84
Q63810 Calcineurin subunit B type I Tau phosphatase 1.36 0.34 0.96 3.84 Not identified
Q76MZ3 Serine/threonine-protein phosphatase 2A Tau phosphatase 1.25 0.58 0.87 1.88 0.73
Table 2. Proteomics of sarkosyl-insoluble tau. Tau-associated proteins quantified in the detergent-insoluble 
fractions of the mouse and human brain. The presented proteins have been selected for their documented roles 
in the regulation and binding of tau. Phosphorylation sites are reported according to the human isoform of tau 
with 441 amino acids.
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shown to precede neurofibrillary pathology in rat models of overexpression19 and inducible expression38 of 
mutant APP/PS1. Supporting this continuum of AD pathology, increased [18F]Flortaucipir binding levels and 
elevated argyrophilic signal succeeded the deposition of neocortical Aβ in APPswe/PS1dE9 mice. Gallyas- and 
thioflavin-S-positive inclusions, in particular, were observed by 18 months of age, when Aβ plaque load has been 
shown to plateau in the neocortex of APPswe/PS1dE9 mice3. These data suggest that the amyloidogenic processing 
of APP is sufficient to induce tau pathology in models of familial AD. The central role of amyloidosis is further 
supported by the fact that ageing alone did not induce neurofibrillary lesions in wild-type animals. In agreement 
with cross-sectional data showing age-dependent accumulation of tau in cognitively unimpaired subjects39–42, tau 
solubility was decreased in 24 vs. 3-month-old wild-type mice. However, a combination of fibrillar, insoluble and 
hyperphosphorylated tau was exclusively observed in APPswe/PS1dE9 mice. These data show that age-related tau 
accumulation can be distinguished from AD tau within the murine life-span, with cerebral amyloidosis driving 
the distinction in models of familial AD.
Phosphorylation is the most extensively studied tau PTM43. Evidence suggests that the phosphorylation pattern 
of specific tau epitopes is associated with distinct morphological stages of NFT formation. Phosphorylation at T231 
occurs earlier compared to other sites35,44, increasing with advancing Braak stage in the transentorhinal region and the 
medial temporal cortex of AD patients44,45. The T231 phospho-residue is present in all types of pathological tau, from 
pre-fibrillar to the NFT stage46. Phosphorylation at S396 and S404, the epitopes recognized by the PHF-1 antibody, 
has been most commonly associated with fibrillar tau and extracellular NFTs34,47. The identification of the aforemen-
tioned epitopes in the sarkosyl-insoluble proteome of APPswe/PS1dE9 mice indicates that murine tau undergoes the 
complete sequence of phosphorylation events that have been associated with the development of cytoskeletal pathol-
ogy in AD, substantiating the detection of Gallyas- and thioflavin-S-positive lesions in aged transgenic animals48. 
Although the possibility of phosphorylation at additional tau epitopes should not be excluded, our data highlight 
pT231, pS238, pS396, pS400 and pS404 as sites of specific interest for targeting pathological tau phosphorylation in 
familial AD. An imbalance between tau-associated kinases and phosphatases is likely to underlie hyperphosphoryl-
ation in the APPswe/PS1dE9 model. Impaired de-phosphorylation mechanisms appear to be particularly important, as 
evidenced by the reduced levels of phosphatase 2 A (PP2A) and calcineurin (CaN; PP2B) in 24-month-old transgenic 
vs. wild-type mice. Both PP2A and CaN are known to interact with PHF tau49, de-phosphorylating it at several residues, 
including pS396 and pS40450,51. It is important to note that these enzymes were elevated by physiological ageing in the 
sarkosyl-insoluble proteome of wild-type animals, which suggests that increasing the level and/or activity of phos-
phatases may hold potential for the management of tau pathology in AD52.
Figure 5. Gene Ontology (GO) enrichment analysis of the sarkosyl-insoluble proteome. (A) Enriched cellular 
components; (B) Enriched molecular functions; (C) Top 10 enriched pathways based on protein upregulation 
in 24-month-old TG vs. WT mice, according to the Kyoto Encyclopaedia of Genes and Genomes (KEGG); 
(D) Top 10 enriched KEGG pathways based on protein downregulation in 24-month-old TG vs. WT mice. 
Functional annotation clustering was generated by using DAVID software. Maximum enrichment probability 
(P value) was based on an EASE score threshold value of 0.05.
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Figure 6. Validation of pS404, pT231 and 3R tau. (A) Immunoblotting of sarkosyl-insoluble tau with rabbit primary 
antibody against phospho-Ser404 (1:200; OAAF07796, Aviva Systems Biology). The entire membrane is shown. 
Hyperphosphorylation at the S404 residue was exclusively observed in 24-month-old APPswe/PS1ΔE9 mice (TG 
24 M, lane 8). Lanes are labelled as follows: Marker: 1, 14; AD: 3; non-AD: 5; WT 24 months: 6; TG 24 months: 8; 
WT 3 months: 10; TG 3 months: 12; Empty: 2, 4, 7, 9, 11, 13. (B) ELISA of pT231 tau. Soluble pT231 tau was present 
in the neocortex of both WT and TG mice. Phosphorylation at T231 was only observed in the sarkosyl-insoluble 
fraction from 24-month-old APPswe/PS1ΔE9 mice. Results are expressed as arbitrary units (U), normalized to total 
protein concentration. (C) Immunohistochemistry of pT231 tau in coronal, 50 µm-thick brain sections from 3- 
and 18-month-old WT and TG mice. Black arrows point to CA1 pyramidal neurons, which were more strongly 
immunolabelled in 18 vs. 3-month-old animals, irrespective of genotype. Scale bar: 200 µm. The inserts show higher 
magnifications of layer V neurons in the temporal cortex, with black arrowheads pointing to tangle-like structures 
in aged APPswe/PS1ΔE9 mice. Note reduced dendritic staining in 18 vs. 3-month-old animals. Scale bar: 10 µm. 
White arrows point to puncta of pT231 immunoreactivity within a plaque-like structure, observed exclusively in the 
neocortex of TG mice. Scale bar: 20 µm. Abbreviations: CA1: cornu ammomis field 1; ec: external capsule; o- striatum 
oriens; p: striatum pyramidalis; r: striatum radiatum. (D) ELISA of 3R tau. Low levels of soluble 3R tau were present 
in the neocortex of both WT and TG animals. Sarkosyl-insoluble 3R tau was only observed in 24-month-old APPswe/
PS1ΔE9 mice. Results are expressed as arbitrary units (U), normalized to total protein concentration.
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Although the literature on the regulation of tau isoforms in AD remains scarce, a prevalence of 3R tau 
in the composition of NFTs has been observed in the AD hippocampus by immunohistochemical and bio-
chemical methods16. Moreover, a shift from 4R to 3R isoforms has been associated with the morphological 
evolution of tau-positive neurons from a pre-tangle to the NFT stage53. In the present study, a 3R isoform of 
tau was preferentially sequestered into the sarkosyl-insoluble proteome of APPswe/PS1dE9 mice, supporting 
the notion that neurofibrillary pathology is associated with tau isoform imbalances. Similar observations 
have been made in transgenic mice overexpressing non-mutated 3R TAU54 or human TAU on a tau knock-
out background8. These models develop filamentous pathology that is primarily composed of 3R tau, in an 
age-dependent manner. Thus, any deviation from the physiological ratio of 4R/3R tau is likely sufficient for 
initiating tau aggregation, in both TAU overexpressing and APPswe/PS1dE9 mice. However, the shift in tau 
isoform expression occurs downstream of Aβ accumulation in the familial AD model, whereas TAU overex-
pressing mice do not exhibit amyloidosis. In addition, TAU in AD is neither overexpressed, nor mutated55. 
Therefore, the pathophysiology that differentiates AD from primary tauopathies is preferentially modeled 
by APPswe/PS1dE9 mice, which reproduce the temporal relationship between aberrant APP processing and 
tau aggregation in familial AD.
The identification of tau isoform-B, which is predominantly expressed in the fetal mouse brain, indicates 
that immature tau isoforms participate in AD tauopathy56, and implicates aberrant transcription and translation 
mechanisms in the disease process. A re-induction of fetal tau may be attributed to the deregulation of core splic-
ing machinery, which was marked in this study and considered to occur early and selectively in AD57. Moreover, 
as the selection of splice sites is determined by canonical sequences encoded into the genome, the re-expression 
of fetal isoforms might be a consequence of aberrant cell cycle re-entry58. Cell cycle proteins that were deregulated 
in an age- and genotype-specific manner in this study include Sub1, cdc42, CEND1, Histone H3 and nucleolin 
(Supplementary Dataset S4). Clearly, the exact mechanisms underlying tauopathy in AD cannot be resolved by 
the present set of experiments. Our data demonstrate, however, that the formation of PHF tau is associated with 
loss of regulatory control over tau splicing in vivo, which may have important implications for the origins and 
management of tauopathy in AD.
The limitations associated with the overexpression of mutant APP and/or PSEN have been discussed pre-
viously2. To exclude the possibility that tauopathy is an artefact of overexpression, it would be important to 
determine whether it develops in second-generation amyloidosis models, carrying AD-related mutations in 
physiologically expressed genes. Moreover, it is becoming increasingly recognised that the familial and sporadic 
forms of AD are not equivalent, despite sharing common clinical and histopathological features59. For example, 
positron emission tomography (PET) with [11C]PIB shows accumulation of Aβ fibrils in the cerebellum of famil-
ial AD cases, which is not typical of sporadic AD60. Cerebellar deposition of hyperphosphorylated tau has been 
observed in AD cases harbouring the PSEN1 E280A mutation, but not in sporadic AD61. Thus, the pronounced 
cerebellar involvement in APPswe/PS1ΔE9 mice, which are known to accumulate Aβ in this region62, suggests that 
the model shows face validity for the familial, rather than sporadic forms of AD. Practical considerations in 
using amyloidosis models to study tau pathology include long waiting times for the accumulation of endoge-
nous murine tau, and mouse-on-mouse/antibody specificity issues, which is a subject of ongoing debate in the 
tau literature63,64. In addition, all the techniques used in this study measured significantly lower levels of tau 
pathology in APPswe/PS1ΔE9 mice compared to human AD tissue. This was particularly evident in the proteomics 
data, where levels of sarkosyl-insoluble total tau were not different between APPswe/PS1ΔE9 and control mice, but 
were > 30-fold elevated in AD vs. non-AD subjects. Studies estimating65 and measuring66 the amount of insoluble 
tau protein in the human AD brain show that tau levels are significantly higher than control in symptomatic AD 
patients, but not in patients with prodromal or preclinical AD. It might thus be that the tau pathology we detect 
in APPswe/PS1ΔE9 mice corresponds to early stage AD.
Despite these limitations, our data show that Aβ aggregation precedes tau-associated molecular and patho-
logical changes in murine models of familial AD. The progressive accumulation of fibrillar tau can be detected 
by tools that are employed for the evaluation of PHF tau clinically, such as the Gallyas silver stain and [18F]
Flortaucipir. The observed pathology occurs in the absence of TAU mutations or overexpression, and is charac-
terized by protein hyperphosphorylation and deposition of 3R tau. The aforementioned similarities with human 
AD argue for repositioning amyloidosis models as tools of translational relevance for the mechanistic study of the 
interplay between Aβ and tau pathology in AD.
Methods
Ethical approval. All methods regarding the use of animal and human tissue were performed in accordance 
with relevant guidelines and regulations. Mouse tissue: All procedures complied with Danish law (Bekendtgørelse 
af lov om dyreforsøg, LBK nr 1306 af 23 nov 2007) and European Union directive 2010/63/EU, regulating animal 
research. Ethical permission was granted by the Animal Ethics Inspectorate of Denmark (nr 2011/561-1950). 
Human tissue: Fresh-frozen samples from the middle frontal gyrus were obtained from the Maritime Brain Tissue 
Bank, Department of Medical Neuroscience, Faculty of Medicine, Dalhousie University, Sir Charles Tupper 
Building, 5850 College Street, Halifax Nova Scotia B3H 4R2. Ethical approval was obtained from the Nova Scotia 
Health Authority Research Board in Halifax, Canada, and the Danish Biomedical Research Ethical Committee of 
the region of Southern Denmark (Project ID: S-20070047). Informed, written consent forms were obtained for 
all subjects.
Animals and tissue sectioning. APPswe/PS1ΔE9 mice express human APP harbouring the Swedish dou-
ble mutations (KM670/671NL) and PSEN1 lacking exon 9 (APPswe/PS1ΔE9), both under control of the mouse 
prion protein promoter67. The mice were originally purchased from the Jackson Laboratories (MMRRC Stock 
No: 34832-JAX), and were bred and maintained as hemizygotes on a C57BL/6 J background in the Biomedical 
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Laboratory of the University of Southern Denmark. Animals were group-housed (4–8/cage), in a temperature 
(21 ± 1 °C) and humidity controlled environment (45–65%), under a 12:12 h light:dark cycle (lights on: 7 am). 
Food and water were available ad libitum.
Female APPswe/PS1ΔE9 mice were used at 3, 6, 12, and 18 months of age. Sex- and age-matched wild-type (WT) 
littermates were used as controls. Both male and female mice were used in the 24-month-old groups (n = 6–9/
genotype & age-group, total animal number: 71). The animals were euthanized by cervical dislocation, and brains 
immediately removed and bisected along the midline. Right hemispheres were frozen in isopentane on dry-ice 
(−30 °C). The olfactory bulb, striatum, cortex, hippocampus, diencephalon, brainstem and cerebellum from the 
left hemisphere were dissected on a petri dish on ice, collected in Eppendorf® tubes, and frozen on dry-ice. The 
tissue was stored at −80 °C until use.
Sectioning was carried out at −17 °C using a Leica CM3050S cryostat (Leica Biosystems GmbH). Consecutive, 
20 µm-thick sagittal sections were collected at 300 µm intervals. The sections were mounted onto ice-cold 
SuperfrostTM Plus slides (Thermo Fisher Scientific), dried at 4 °C in a box containing silica gel for at least 2 h, and 
stored at −80 °C for future experiments. Every 13th and 14th section was collected in Eppendorf® tubes for RNA 
extraction with TrizolTM.
Fresh-frozen coronal brain sections of male and female, 20-month-old WT and hemizygote Tg2576 mice, 
harbouring the Swedish double mutations, were provided by the Centre for Biological Sciences, University of 
Southampton, U.K. (n = 2–3/group).
Human tissue. Tissue from the middle frontal gyrus of a sporadic, AD-confirmed patient [BB08-002, 
Female, 80 years old, post-mortem interval (PMI): 9 h, CERAD: Frequent; Braak: V] and a non-AD subject (BB16-
023, Female, 83 years old, PMI unknown, CERAD: Sparse; Braak: II) were processed along with the murine sam-
ples in order to compare tau pathology between transgenic mouse and human AD tissue. The AD and non-AD 
samples were chosen for their abundance and complete lack of tau pathology respectively, as assessed by Gallyas 
silver staining and [18F]Flortaucipir autoradiography.
(Immuno)histochemistry, immunoblotting, ELISA. The Gallyas silver stain was performed according 
to Kuninaka et al.68. Thioflavin-S according to Sun et al.48. Standard protocols were used for tau immunoblotting, 
immunohistochemistry and ELISA. The following primary antibodies were used: rabbit total Tau (1:1000; A0024, 
Dako Agilent), rabbit Phospho-Tau Thr231 (1:500; #701056, Thermo Fisher Scientific), rat anti 3R-Tau (1:1000; 
clone 2A1-1F4; 016-26581, Wako), rabbit Phospho-Ser404 (1:200; OAAF07796, Aviva Systems Biology). Detailed 
protocols are provided in Supplementary Information.
Autoradiography and proteomics. [18F]Flortaucipir autoradiography was performed accord-
ing to Marquié et al.69, proteomics according to Kempf et al.70 and Thygesen et al.71. Details are provided in 
Supplementary Information.
RT-qPCR. For reverse transcription quantitative polymerase chain reaction (RT-qPCR), TrizolTM-isolated 
RNA (2 μg) from brain sections of WT and TG mice was reverse-transcribed to cDNA, by using the Applied 
BiosystemsTM high-capacity cDNA transcription kit (Thermo Fisher Scientific). Samples were analysed in trip-
licate on a StepOnePlusTM Real-Time PCR system (Applied BiosystemsTM, Thermo Fisher Scientific). Each 
20 µL sample contained nuclease-free H2O (Thermo Fisher Scientific), 1x Maxima SYBR® green/probe mas-
ter mix (Thermo Fisher Scientific), 500 nM forward and reverse primers (TAG Copenhagen A/S), 4x diluted 
cDNA for Mapt, undiluted cDNA for Mapt Isoform-B, and 10x diluted cDNA for hypoxanthine phosphoribo-
syltransferase (Hprt1), which was used as a reference gene. Hprt1 sequences72 and mouse-specific Mapt prim-
ers spanning exon 10 have been described previously17. New primers were designed for isoform-B, forward: 
CAAGGACAGAGTCCAGTCGAAG; reverse: AAGCAGCTTTTCCCTGCTTGG. Conventional PCR cycling 
conditions were used [95 °C (10 min), 40 cycles of 95 °C (15 s)/60 °C (1 min)], followed by a melt curve. After 
normalization to Hprt1, data were expressed as fold change from the mean value of the 3-month-old WT samples. 
Nuclease-free H2O and genomic DNA were used as controls.
Isolation of sarkosyl-insoluble tau. Left brain hemispheres from two mice per group were pooled and 
weighed (467.1 ± 3.1 mg). The tissue was thoroughly homogenised with a motor driven Potter-Elvehjem tissue 
grinder (WHEATON), in a 5-fold excess (v/w) of 10 mM Tris-HCl buffer (pH 7.4), containing 800 mM NaCl, 
1 mM EGTA, 10% sucrose, protease inhibitors (cOmpleteTM Protease Inhibitor; Roche Diagnostics) and phos-
phatase inhibitors (PhosSTOPTM; Roche Diagnostics; H buffer). The homogenate was centrifuged at 4 °C for 
20 min in a refrigerated ultracentrifuge (27,000 × g; Sorvall RC M150 GX). The supernatant was decanted and 
kept on ice, the pellet (P1) suspended in 5 vol of H-buffer and re-centrifuged at 27,000 × g for 20 min (4 °C). The 
combined supernatants (S1) were brought to 1% sarkosyl in H buffer and incubated for 2 h at 37 °C in a C24 incu-
bator shaker (100Rpm; New Brunswick Scientific). Following centrifugation at 200,000 × g for 40 min (4 °C), the 
sarkosyl-soluble fraction was decanted and kept on ice, and the sarkosyl-insoluble pellet suspended in H buffer, 
containing 1% CHAPS hydrate (Sigma Aldrich Co.). After filtering through acetate cellulose filters (0.45 µm; 
VWR International), the filtrates were centrifuged at 200,000 g for 70 min, and the final pellet suspended in 250 µL 
dH2O. Aliquots of 150 µL from the P1, S1, sarkosyl soluble and insoluble fractions were kept for determining tau 
protein levels. Samples were stored at −80 °C until further processed.
Tau meso scale. Tau protein concentration in soluble and insoluble fractions was measured with the mouse 
Total Tau kit (K151DSD-1; Mesoscale Diagnostics LLC). The anti-mouse monoclonal antibody used for detec-
tion binds between amino acids 150–200 of Tau, but the clone number and exact epitope recognition site(s) are 
proprietary. Plates were processed in a SECTOR® Imager 6000 plate reader (Meso Scale Diagnostics LLC), and 
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data acquired with Discovery Workbench software (v.4.0; Meso Scale Diagnostics LLC). Results are presented as 
pg of tau/mg of total protein, the latter measured at A562 nm with a PierceTM BCA protein kit and bovine serum 
albumin as standard (Thermo Fisher Scientific).
Transmission electron microscopy (TEM) of sarkosyl-insoluble tau. Electron microscopy was per-
formed in the Core Facility for Integrated Microscopy, Faculty of Health and Medical Sciences, University of 
Copenhagen, Denmark. Carbon-coated copper grids (200 mesh; Ted Pella Inc.) were glow-discharged with a 
Leica EM ACE 200 (Leica Biosystems Nussloch GmbH), and loaded with 6 µL of sarkosyl-insoluble sample. The 
sample was adsorbed for 1 min, blotted and stained with 2% phosphotungstic acid in dH20 for 2 min. After blot-
ting and a quick wash with dH20, the samples were examined with a Philips CM 100 TEM (Koninklijke Philips 
N.V.), operated at an accelerating voltage of 80 kV. Digital images were acquired at a nominal magnification 
of x180,000, by using an OSIS Veleta digital slow scan 2k × 2k CCD camera and the iTEM software package 
(Olympus Corporation). Filaments shorter and longer than 200 µm were analysed in at least two fields of view 
with ImageJ software. Reported values are mean ± SEM of 70 and 32 PHFs for APPswe/PS1ΔE9 and AD tissue, 
respectively.
Statistical analysis. Parametric testing was employed following inspection of the data for normality with 
the Kolmogorov-Smirnov test in Prism (v6.01; GraphPad Software). Data sets were analyzed by StatisticaTM 
v10 (TIBCO Software Inc., USA). The effects of age, genotype and brain region on the binding levels of [18F]
Flortaucipir were analyzed by three-way ANOVA. Gallyas-positive area fraction and tau gene/protein levels were 
analyzed by two-way ANOVA for the independent factors age and brain region or age and genotype, respectively. 
Where ANOVA yielded significant effects, Bonferroni post-hoc comparisons were used to detect between-group 
regional and age-dependent differences. Levels of sarkosyl-insoluble tau between 24-month-old TG and WT 
mice, and PHF dimensions extracted from TG vs. AD brain were compared by two-tailed independent Student’s 
t-tests. Significance was set at α = 0.05. A 1.3-fold change cut-off value for all TMT ratios was used to rank pro-
teins as up- or down-regulated in the proteomics study73.
Data availability
The proteomics data have been deposited to the ProteomeXchange Consortium74 via the PRIDE partner 
repository with the dataset identifier PXD009306 [username: reviewer39090@ebi.ac.uk; password: HdJxxVxU75]. 
The remaining data generated or analysed during this study are included in the article. Raw data are available 
from the corresponding author upon reasonable request.
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